<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="491">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04798989</url>
  </required_header>
  <id_info>
    <org_study_id>C6463-202</org_study_id>
    <nct_id>NCT04798989</nct_id>
  </id_info>
  <brief_title>A Study of the Effects of CY6463 in Participants With Alzheimer's Disease With Vascular Pathology</brief_title>
  <official_title>A Phase 2a Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CY6463 When Administered to Participants With Alzheimer's Disease and Vascular Pathology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyclerion Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cyclerion Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being conducted to test the safety, tolerability, and pharmacokinetics of the&#xD;
      investigational drug CY6463 compared with placebo in individuals who are aged 60 years or&#xD;
      older and have Alzheimer's disease (AD) along with common cardiovascular risk factors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CY6463 is an investigational drug being developed as a symptomatic and potentially&#xD;
      disease-modifying therapy for Alzheimer's disease (AD) and other serious central nervous&#xD;
      system disorders. As a soluble guanylate cyclase (sGC) stimulator, CY6463 can cross the&#xD;
      blood-brain barrier and boosts the activity of the nitric oxide-soluble guanylate&#xD;
      cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) pathway. This signaling pathway is&#xD;
      important in many aspects of brain health, including in the control of blood flow in the&#xD;
      brain, how brain cells use energy, and how those cells communicate with one another.&#xD;
      Impairment of this pathway is a critical part of the origin of many neurodegenerative&#xD;
      diseases that can cause a loss of brain function including memory and decision-making&#xD;
      abilities. There are clear links between disrupted NO signaling and impaired brain function&#xD;
      in patients with AD and vascular pathology (ADv). (&quot;Vascular pathology&quot; refers to&#xD;
      abnormalities of the blood vessels that are more likely to occur when a person has&#xD;
      cardiovascular risk factors like high blood pressure, diabetes, and/or obesity.) It is&#xD;
      hypothesized that CY6463 may help patients with ADv maintain or recover some of their&#xD;
      original cognitive function.&#xD;
&#xD;
      In this study, participants will be randomized to receive approximately 87 sequential days&#xD;
      (~3 months) of study drug (CY6463 or placebo) once daily (QD) and will complete 7 scheduled&#xD;
      site visits over the course of the study, from Screening through Follow up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">July 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events (TEAEs) from study drug initiation through Follow-up</measure>
    <time_frame>From first dose of study treatment through ~14 (±4) days after the final dose</time_frame>
    <description>TEAE is defined as an adverse event with an onset that occurs after receiving the study drug, until the end of the Follow-up period</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Alzheimer's Disease With Vascular Pathology</condition>
  <arm_group>
    <arm_group_label>CY6463</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CY6463</intervention_name>
    <description>CY6463 Oral Tablet</description>
    <arm_group_label>CY6463</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo Oral Tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provide written informed consent prior to the performance of any protocol-specified&#xD;
             procedure or, if unable to provide informed consent due to cognitive status, provides&#xD;
             assent to participate, with a legally authorized representative (LAR) providing&#xD;
             written informed consent on behalf of the participant.&#xD;
&#xD;
          2. 60 years of age or older&#xD;
&#xD;
          3. Meets core clinical criteria for probable AD dementia according to the 2011 National&#xD;
             Institute on Aging-Alzheimer's Associated guidelines. Can be based on medical history.&#xD;
&#xD;
          4. Mini-Mental State Examination (MMSE) score of 20 to 26 (inclusive)&#xD;
&#xD;
          5. Confirmation of AD pathophysiology&#xD;
&#xD;
          6. At least 2 cardiovascular risk factors per protocol criteria&#xD;
&#xD;
          7. Magnetic resonance imaging (MRI) scan (existing MRI obtained ≤6 months before&#xD;
             Screening is acceptable) findings of mild-to-moderate subcortical small-vessel disease&#xD;
&#xD;
          8. If receiving concomitant or chronic medication(s), has had no change for ≥4 weeks&#xD;
             before study drug initiation and has no plans to alter the regimen(s) during the study&#xD;
&#xD;
          9. If male, agrees to refrain from donating sperm from the Screening visit through 90&#xD;
             days after taking the final study drug dose&#xD;
&#xD;
         10. If male, agrees to use protocol-specified, effective contraception methods from the&#xD;
             signing of the informed consent form (ICF) until ≥90 days after taking the final study&#xD;
             drug dose.&#xD;
&#xD;
         11. If female, is postmenopausal/not of reproductive potential defined per protocol&#xD;
&#xD;
         12. Agrees to the study procedures, including undergoing lumbar puncture for cerebrospinal&#xD;
             fluid (CSF) samples&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Severe visual, auditory, social, or cognitive impairment&#xD;
&#xD;
          2. Dementia-related disorder other than AD or vascular dementia (eg, Parkinson's disease,&#xD;
             Huntington's disease, frontotemporal dementia, schizophrenia, Lewy body dementia)&#xD;
&#xD;
          3. Symptomatic large-vessel disease, symptomatic carotid artery disease, large vessel&#xD;
             infarcts, or strategic lacunar infarcts or infarcts&gt;15 mm&#xD;
&#xD;
          4. History of significant central nervous system (CNS) trauma that has affected brain&#xD;
             function&#xD;
&#xD;
          5. Low blood pressure (BP), defined as systolic BP ≤90 mmHg or diastolic BP ≤60 mmHg.&#xD;
&#xD;
          6. Orthostatic hypotension.&#xD;
&#xD;
          7. Unable to undergo MRI&#xD;
&#xD;
          8. Unable to undergo lumbar puncture procedure&#xD;
&#xD;
          9. Unable to participate in electroencephalography (EEG) protocol due to hearing&#xD;
             impairment or inability to tolerate EEG cap or headphones&#xD;
&#xD;
         10. Uncontrolled or unstable chronic disease&#xD;
&#xD;
         11. Kidney impairment requiring dialysis; history of renal transplant&#xD;
&#xD;
         12. Needs continuous direct medical care and nursing supervision.&#xD;
&#xD;
         13. Family history of short QT syndrome or long QT syndrome&#xD;
&#xD;
         14. Clinically significant cardiac involvement&#xD;
&#xD;
         15. History of cancer. Exceptions: localized cutaneous basal or squamous cell carcinoma in&#xD;
             the last 5 years, low-grade localized prostate/cervical cancers, or previous localized&#xD;
             prostate/cervical cancers that have a low likelihood of recurrence&#xD;
&#xD;
         16. Is not suited for study participation in the clinical judgment of the investigator&#xD;
&#xD;
        Additional inclusion and exclusion criteria apply, per protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chad Glasser, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Cyclerion Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meghan Bratton</last_name>
    <phone>857-338-3339</phone>
    <email>mbratton@cyclerion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Endpoints</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donnell Carmichael</last_name>
      <phone>480-566-9090</phone>
      <email>dcarmichael@clinicalendpoints.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Optimus U Corp</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fermin Nieto</last_name>
      <phone>305-702-0024</phone>
      <email>fermin@optimusu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hawaii Pacific Neurosciences, LLC</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Mitchell</last_name>
      <phone>808-564-6141</phone>
      <email>cmitchell@hawaiineuroscience.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Hope</last_name>
      <phone>859-257-6507</phone>
      <email>Kimberly.Hope@uky.edu</email>
    </contact>
    <contact_backup>
      <last_name>Keisha Jones</last_name>
      <phone>(859) 218-4980</phone>
      <email>kcl.jones@uky.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Cropp</last_name>
      <phone>617-643-4802</phone>
      <email>actrustudies@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kate LaCasse</last_name>
      <phone>617-634-4047</phone>
      <email>klacasse1@mgh.harvard.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2022</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>June 9, 2022</last_update_submitted>
  <last_update_submitted_qc>June 9, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Alzheimer's disease</keyword>
  <keyword>AD</keyword>
  <keyword>ADv</keyword>
  <keyword>CY6463</keyword>
  <keyword>Subcortical small-vessel disease</keyword>
  <keyword>Elderly</keyword>
  <keyword>60 and older</keyword>
  <keyword>Probable AD dementia</keyword>
  <keyword>Vascular dementia</keyword>
  <keyword>Mixed dementia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

